Literature DB >> 33281314

Awake Prone Positioning in COVID-19 Patients.

Prabhanjan Singh1, Prerana Jain1, Himanshu Deewan1.   

Abstract

BACKGROUND: The World Health Organization (WHO) has declared SARS-CoV-2 as pandemic. Patients with COVID-19 present mainly with respiratory symptoms. Prone position has been traditionally used in acute respiratory distress syndrome (ARDS) to improve oxygenation and prevent barotrauma in ventilated patients. Awake proning is being used as an investigational therapy in COVID to defer invasive ventilation, improve oxygenation, and outcomes. Hence, we conducted a retrospective case study to look for benefits of awake proning with oxygen therapy in non-intubated COVID patients.
MATERIALS AND METHODS: A retrospective case study of 15 COVID patients admitted from June 15 to July 1, 2020 to HDU in our hospital was conducted. Cooperative patients who were hemodynamically stable and SpO2 < 90% on presentation were included. Oxygen was administered through facemask, non-rebreathing mask and noninvasive ventilation to patients as per requirement. Patients were encouraged to maintain prone position and target time was 10-12 hours/day. SpO2 and P/f ratio in supine and prone position was observed till discharge. Primary target was SpO2 > 95% and P/f > 200 mm Hg. Other COVID therapies were used according to institutional protocol.
RESULTS: The mean SpO2 on room air on admission was 80%. In day 1 to 3, the mean P/f ratio in supine position was 98.8 ± 29.7 mm Hg which improved to 136.6 ± 38.8 mm Hg after proning (p = 0.005). The difference was significant from day 1 to 10. Two patients were intubated. The mean duration of stay was 11 days.
CONCLUSION: Awake prone positioning showed marked improvement in P/f ratio and SpO2 in COVID-19 patients with improvement in clinical symptoms with reduced rate of intubation. HIGHLIGHTS: Prone position ventilation improves oxygenation by reducing V/Q mismatch.Awake prone positioning has been used along with high-flow oxygen therapy in recent pandemic of SARS-CoV-2 virus for management of mild to moderate cases. HOW TO CITE THIS ARTICLE: Singh P, Jain P, Deewan H. Awake Prone Positioning in COVID-19 Patients. Indian J Crit Care Med 2020;24(10):914-918.
Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.

Entities:  

Keywords:  Awake prone position; COVID-19; Coronavirus; SARS-CoV-2

Year:  2020        PMID: 33281314      PMCID: PMC7689121          DOI: 10.5005/jp-journals-10071-23546

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


Introduction

A novel strain of coronavirus SARS-CoV-2 started from China has now spread to over 200 countries across the world.[1,2] This has been declared as pandemic by the WHO.[3] COVID-19 is primarily a respiratory illness. The symptoms of COVID-19 are from mild flu-like illness to severe acute respiratory distress syndrome (ARDS)-like requiring mechanical ventilation.[2,3] The COVID-19 patients often present with low oxygen saturation requiring supplemental oxygen. However, absence of dyspnea and tachycardia is seen aptly described as “happy hypoxia”.[4-6] Prone ventilation is a recommended recruitment strategy in ARDS for many years in intubated patients.[7-9] In recent time, awake prone position therapy has come up with great benefits. This technique improves oxygenation and decreases the need for invasive ventilation.[10,11] With the global pandemic putting a strain on many countries’ resources, a high-flow oxygen therapy with awake prone position seems to be of low risk, easy to perform, and low cost management strategy in non-intubated patients.[11] So, we conducted a retrospective observational study in high-dependency unit (HDU) in our hospital to see the effect of awake prone position therapy in COVID-19 patients.

Materials and Methods

Approval for the study and a waiver of the consent was obtained from the institutional ethics committee. This case series describes 15 patients with COVID-19 pneumonia requiring oxygen supplementation admitted from June 15 to July 1, 2020 in HDU in our hospital. All patients were diagnosed with COVID-19 disease by RT-PCR (real-time polymerase chain reaction) technique. Patients who were hemodynamically stable, SpO2 <90% on presentation, and able to adjust their prone position were included in the study. Those who were hemodynamically unstable, drowsy, or uncooperative were excluded from the study. Continuous vital signs [electrocardiogram (ECG), SpO2, non-invasive blood pressure (NIBP), respiratory rate, and temperature] were monitored. Intra-arterial line was inserted for frequent arterial blood gas measurement to monitor PaO2/fiO2 (P/f) ratio. Oxygen therapy was initiated with face mask at 5 L/minute and the flow rate was titrated to reach the target SpO2 >94%. If the target SpO2 was not achieved then non-rebreathing mask (NRBM) at 10 to 15 L/minute was considered. Noninvasive ventilation (NIV) was started if respiratory distress worsened or hypoxemia not alleviated by standard oxygen therapy. Tracheal intubation and invasive ventilation were considered when the patient deteriorated, i.e., altered sensorium, hypotension, or shock. Awake prone position was explained to every patient and they were encouraged to spend as much time in prone position as they could tolerate. The target time in prone position was 10 to 12 hours per day. Proning was performed 1 hour after meals to avoid gastrointestinal side effects. Specific COVID-19 treatment was given to all patients according to the institutional protocol which included remdesivir, tocilizumab, dexamethasone, and low-molecular weight heparin. Target for discharging from HDU was SpO2 of >95% and P/f ratio of >200 mm Hg. Patients were shifted to ward when they were weaned off oxygen at least for 24 hours.

Results

The mean age of the sample was 51.5 years. Eight patients had a history of systemic comorbidities like diabetes (DM) and hypertension (Htn). Only 6 patients out of 15 presented with tachypnea despite low SpO2 depicting the phenomenon of “silent hypoxemia” (Table 1).
Table 1

Overview of cases

Case no.Age/genderComorbiditiesRoom air SpO2 (%)TachypneaMode of oxygen therapyDuration of HDU stay (days)Intubation requiredOutcome
  148/M76AbsentNRBM @ 15 L/minute10NoDischarged to ward
  253/MDM, Htn72AbsentNRBM @ 15 L/minute13NoDischarged to ward
  359/MDM84AbsentNRBM @ 10 L/minute f/b NIV f/b IPPV20YesExpired on D20
  457/MDM, Htn, obesity79AbsentNRBM @ 15 L/minute6NoDischarged to ward
  558/MDM67PresentNIV @ 0.8 FiO29NoDischarged to ward
  673/MDM, Htn72PresentNIV @ 0.7 FiO212NoDischarged to ward
  758/M88PresentNIV @ 0.8 FiO215NoDischarged to ward
  854/MDM80PresentNIV @ 0.9 FiO2 f/b IPPV22YesExpired on D22
  957/M90PresentNIV @ 0.6 FiO214NoDischarged to ward
1039/M94AbsentFace mask @ 10 L/minute3NoDischarged to ward
1147/F68PresentNIV @ 0.9 FiO28NoDischarged to ward
1267/MDM87AbsentFace mask @ 5 L/minute10NoDischarged to ward
1334/M67AbsentNRBM @ 15 L/minute7NoDischarged to ward
1437/MDM85AbsentFace mask @ 10 L/minute f/b NRBM @ 15 L/minute10NoDischarged to ward
1532/M89AbsentFacemask @ 8 L/minute7NoDischarged to ward
Mean ± SD51.5 ± 11.980 ± 0.0910 ± 5.13
The mean SpO2 on room air on admission was 80%. Oxygen therapy was started immediately through face mask to four patients (26.6%), NRBM to five patients (33.3%), and NIV to six patients (40%). Thirteen patients were successfully weaned off in mean duration of 10 days and were discharged to ward. Rest two (13%) required invasive positive pressure ventilation (IPPV) and were shifted to intensive care unit (ICU) (Fig. 1).
Fig. 1

Modes of oxygen therapy used for COVID-19 patients

SpO2 improved as soon as oxygen therapy was started. A further rise in SpO2 was seen with change in the position from supine to prone owing to the reduction in intrapulmonary shunting. This increasing SpO2 trend with prone positioning was seen in all patients (Table 2).
Table 2

Median SpO2 (%) with oxygen therapy in supine and prone positions

On presentationMedian SpO2 (%) with oxygen therapy (Interquartile range in parenthesis)
CasesRoom air SpO2 (%)Day 1–3Day 4–6Day 7–9Day 10–till discharge
Supine positionProne positionSupine positionProne positionSupine positionProne positionSupine positionProne position
Case 17693 (88–94)96 (93–97)94 (92–96)96 (94–97)95 (96–98)97 (96–99)97 (97–99)97 (96–99)
Case 27292 (86–94)95 (92–97)92 (89–95)95 (93–97)94 (93–96)96 (95–98)98 (97–100)99 (98–100)
Case 38488 (85–92)91 (88–93)88 (87–90)90 (88–91)87 (86–94)90 (89–96)
Case 47989 (88–93)92 (88–94)93 (92–95)95 (93–96)96 (94–97)97 (95–99)
Case 56785 (82–90)89 (86–91)87 (85–90)90 (88–92)92 (91–94)95 (94–98)
Case 67289 (84–92)92 (90–94)91 (89–93)93 (92–94)93 (92–95)94 (93–96)96 (95–98)98 (96–99)
Case 78892 (89–95)95 (93–96)93 (90–94)95 (94–96)95 (94–97)97 (96–99)98 (95–99)98 (97–99)
Case 88087 (84–91)89 (87–91)
Case 99094 (90–96)96 (93–97)95 (93–96)97 (95–98)98 (97–99)99 (97–100)
Case 109496 (95–98)98 (94–98)99 (98–100)99 (98–100)
Case 116889 (84–90)93 (90–94)92 (89–93)95 (93–96)97 (96–99)99 (97–100)
Case 128791 (88–94)94 (91–95)93 (91–95)96 (94–97)95 (94–96)97 (96–99)97 (96–99)98 (97–100)
Case 136788 (85–92)93 (90–94)92 (90–94)95 (92–96)97 (96–99)99 (98–99)
Case 148590 (87–94)94 (89–95)93 (92–96)96 (93–97)96 (95–98)97 (95–99)98 (97–100)99 (97–100)
Case 158992 (90–95)95 (92–96)94 (92–95)97 (96–98)99 (98–100)99 (97–100)
In first 3 days, the mean P/f ratio in supine position was 98.8 ± 29.7 mm Hg which improved to 136.6 ± 38.8 mm Hg after proning (p value = 0.005). Similar trend was observed over next days where mean P/f ratio in supine position were 142.4 ± 40.9, 178.3 ± 38.3, and 210.3 ±37.9 which increased to 173.9 ± 46.6, 214.8 ± 44.2, and 218.6 ± 32.5 from day 4 to 6, day 7 to 10, and day 11 to till discharge, respectively (p value = 0.050, 0.033, and 0.692). The difference was significant in the initial days from day 1 to day 10. However, this difference was insignificant after 10 days till the time of discharge (Table 3). The mean duration of stay was 10 days in HDU (Fig. 2).
Table 3

Average P/f ratio in supine and prone positions

Average P/f ratio (mm Hg)Case 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8Case 9Case 10Case 11Case 12Case 13Case 14Case 15Mean ± SDp value
Day 1–3Supine position  84.2125.5  67.9  65.7  68.5  91.7  77.483.1163.3142.7  80.8  88.9100.7112.3130.598.8 ± 29.70.005
Prone position170.5170.4120.6  85.8108.8116.8  98.396.7171.4213.3100.6105.7175.4152.6162.8136.6 ± 38.8
Day 4–6Supine position170.1101.3100.5147.6123.6125.4  87.6Intubated on day 3151.4220.6104.5130.4170.8182.6157.4140.9 ± 37.40.050
Prone position234.2122.3120.9157.7148.8152.8115.6206.2278.4164.5153.3182.5215.7182.2173.9 ± 46.6
Day 7–9Supine position250.4158.8118.8212.5154.2140.6130.7204.7190.3154.8194.6210.5197.5178.3 ± 38.30.033
Prone position305.7190.8156.9245.6216.2180.5151.6250.6225.8168.8230.5251.8217.8214.8 ± 44.2
Day 10–till dischargeSupine position270.4190.2Intubated on day 10212.5160.8195.2232.7210.3 ± 37.90.692
Prone position280.2220.4230.7180.4220.6240.7218.6 ± 32.5
Fig. 2

Range of P/f ratio in individual cases during the course of treatment

Modes of oxygen therapy used for COVID-19 patients Overview of cases Median SpO2 (%) with oxygen therapy in supine and prone positions Only 2 patients out of 15 required intubation in view of progressing disease or deteriorating consciousness who were excluded from the study.

Discussion

COVID-19 pneumonia is a specific disease whose distinctive features are severe hypoxemia often associated with near normal respiratory system compliance.[12] Hence, an unusual phenomenon of “happy hypoxia” or “silent hypoxemia” is seen in many patients.[5,6] Patients appear to be normally functioning without dyspnea and tachycardia despite being hypoxemic. Patients with severe disease often require high oxygenation support. High-flow oxygen therapy and noninvasive positive pressure ventilation have been used. Some patients may develop ARDS and warrant invasive ventilation.[13] Hence, any therapy which can improve oxygenation and reduce lung injury should be used to improve the survival rate. The initial approach for managing such patients was to intubate early to decrease the work of breathing and prevent patient self-inflicted lung injury (P-SILI).[12,14] Later on, it was found that the complications and mortality were high with this approach.[15,16] Moreover, during the pandemic time, it led to resources and manpower crisis, especially in developing nations. The role of prone position ventilation is well established in classical ARDS.[8] In prone position, there is hemogeneous distribution of the gas which reduces the ventilation-perfusion (V/Q) mismatch. This reduces the intrapulmonary shunt and opens the atelectatic lung areas with adequate sputum drainage, improving oxygenation.[7,9] Also, the transpulmonary pressure gradient is reduced which decreases barotrauma.[9] In recent studies, awake prone positioning was used in emergency department and ward settings to maintain oxygenation of COVID-19 patients.[17,18] Studies have shown to avoid intubation with early application of prone positioning with high-flow nasal cannula (HFNC) in moderate ARDS patients.[19-21] In our study, we also found that the median P/f ratio significantly improved from supine to prone position from day 1 to day 10. We were able to reduce the intubation rates, avoid the problems related to invasive ventilation and with use of sedation and neuromuscular blockers. The mean duration of stay was 10 days in HDU. Two out of 15 patients who required intubation were shifted to ICU and subsequently expired. Most patients tolerated the prone position well and reported the improvement in symptoms. We are also cognizant that other COVID-19 therapies could have modified the disease course as well.[22-25] Hence, awake proning with high-flow oxygen therapy proved to be a low risk, easy to perform, easily tolerated, and low cost rescue therapy in COVID-19 patients. There was no randomization to a control group. Sample size of the study was small. High-flow nasal cannula was not available in our set up which is highly recommended.

Conclusion

Awake prone positioning showed marked improvement in P/f ratio and SpO2 in COVID-19 patients with improvement in clinical symptoms and minimal complications. We were able to reduce the intubation rates which helped in offloading the resource and manpower burden on healthcare system in pandemic. Average P/f ratio in supine and prone positions Range of P/f ratio in individual cases during the course of treatment
  23 in total

1.  Prone positioning in severe acute respiratory distress syndrome.

Authors:  Claude Guérin; Jean Reignier; Jean-Christophe Richard; Pascal Beuret; Arnaud Gacouin; Thierry Boulain; Emmanuelle Mercier; Michel Badet; Alain Mercat; Olivier Baudin; Marc Clavel; Delphine Chatellier; Samir Jaber; Sylvène Rosselli; Jordi Mancebo; Michel Sirodot; Gilles Hilbert; Christian Bengler; Jack Richecoeur; Marc Gainnier; Frédérique Bayle; Gael Bourdin; Véronique Leray; Raphaele Girard; Loredana Baboi; Louis Ayzac
Journal:  N Engl J Med       Date:  2013-05-20       Impact factor: 91.245

2.  Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.

Authors:  R Gentry Wilkerson; Jason D Adler; Nirav G Shah; Robert Brown
Journal:  Am J Emerg Med       Date:  2020-05-22       Impact factor: 2.469

3.  Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19: a case series.

Authors:  Qiancheng Xu; Tao Wang; Xuemei Qin; Yanli Jie; Lei Zha; Weihua Lu
Journal:  Crit Care       Date:  2020-05-24       Impact factor: 9.097

Review 4.  A Review of Coronavirus Disease-2019 (COVID-19).

Authors:  Tanu Singhal
Journal:  Indian J Pediatr       Date:  2020-03-13       Impact factor: 1.967

5.  Prone Position in Management of COVID-19 Patients; a Commentary.

Authors:  Parisa Ghelichkhani; Maryam Esmaeili
Journal:  Arch Acad Emerg Med       Date:  2020-04-11

6.  Why COVID-19 Silent Hypoxemia Is Baffling to Physicians.

Authors:  Martin J Tobin; Franco Laghi; Amal Jubran
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 21.405

7.  Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study.

Authors:  Tariq Kewan; Fahrettin Covut; Mohammed J Al-Jaghbeer; Lori Rose; K V Gopalakrishna; Bassel Akbik
Journal:  EClinicalMedicine       Date:  2020-06-20

Review 8.  Caution about early intubation and mechanical ventilation in COVID-19.

Authors:  Martin J Tobin; Franco Laghi; Amal Jubran
Journal:  Ann Intensive Care       Date:  2020-06-09       Impact factor: 6.925

9.  COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Authors:  Luciano Gattinoni; Davide Chiumello; Pietro Caironi; Mattia Busana; Federica Romitti; Luca Brazzi; Luigi Camporota
Journal:  Intensive Care Med       Date:  2020-04-14       Impact factor: 17.440

10.  Basing Respiratory Management of COVID-19 on Physiological Principles.

Authors:  Martin J Tobin
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

View more
  4 in total

1.  Prone Positioning in Patients With COVID-19: Analysis of Multicenter Registry Data and Meta-analysis of Aggregate Data.

Authors:  Anastasios Kollias; Konstantinos G Kyriakoulis; Vasiliki Rapti; Ioannis P Trontzas; Thomas Nitsotolis; Konstantinos Syrigos; Garyphallia Poulakou
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 2.  COVID-19 pneumonia: pathophysiology and management.

Authors:  Luciano Gattinoni; Simone Gattarello; Irene Steinberg; Mattia Busana; Paola Palermo; Stefano Lazzari; Federica Romitti; Michael Quintel; Konrad Meissner; John J Marini; Davide Chiumello; Luigi Camporota
Journal:  Eur Respir Rev       Date:  2021-10-20

Review 3.  The Application of Awake-Prone Positioning Among Non-intubated Patients With COVID-19-Related ARDS: A Narrative Review.

Authors:  Lingli Chen; Yan Zhang; Yi Li; Chao Song; Fengyu Lin; Pinhua Pan
Journal:  Front Med (Lausanne)       Date:  2022-02-07

4.  Correlation of Serum Albumin Level to Lung Ultrasound Score and Its Role as Predictors of Outcome in Acute Respiratory Distress Syndrome Patients: A Prospective Observational Study.

Authors:  Souvik Chaudhuri; Sagar S Maddani; Shwethapriya Rao; Sirish Gauni; N R Arjun; Pratibha Todur; Nitin Gupta
Journal:  Crit Care Res Pract       Date:  2021-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.